These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Combination therapy with ZDV and interferon-alpha-2a promotes tumor regression.
    Journal: J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):51. PubMed ID: 11363699.
    Abstract:
    Combined therapy with an intermediate dose of interferon-alpha-2a and ZDV effectively fights tumors in patients with nonvisceral AIDS-related Kaposi's sarcoma. Treatments are generally well tolerated, with the most common adverse effects being neutropenia, anemia, elevated serum transaminase, and weight loss. Patients with CD4+ counts above 100 respond better than those with lower counts, but the protocol should be considered regardless of the CD4+ count.
    [Abstract] [Full Text] [Related] [New Search]